SON-080
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Conditions
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Trial Timeline
Oct 27, 2022 → Mar 17, 2024
NCT ID
NCT05435742About SON-080
SON-080 is a phase 1/2 stage product being developed by Sonnet BioTherapeutics for Chemotherapy-induced Peripheral Neuropathy (CIPN). The current trial status is terminated. This product is registered under clinical trial identifier NCT05435742. Target conditions include Chemotherapy-induced Peripheral Neuropathy (CIPN).
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-induced Peripheral Neuropathy (CIPN) were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
9
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05435742 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Chemotherapy-induced Peripheral Neuropathy (CIPN)